Table 3.

Immunogenicity rates over the 5-year LTE period. Values are n/N (%) unless otherwise specified.

Immunogenicity CategoryCTLA-4 and Possibly IgIg and/or Junction Region
Any positive response, including posttreatment229/1365 (16.8)142/1365 (10.4)
Positive response while receiving treatment123/1358 (9.1)122/1358 (9.0)
Positive response posttreatment*142/1111 (12.8)69/1111 (6.2)
IR (95% CI) while receiving treatment2.56 (2.13–3.06)2.52 (2.10–3.01)
Persistent response while receiving treatment**19/1330 (1.4)47/1330 (3.5)
Neutralizing antibody response while receiving treatment61/1358 (4.5)NA

  • ↵* 28, 85, or 168 days after the discontinuation of study drug.

  • ↵** 2 consecutive positive responses ≥ 12 weeks apart. CTLA-4: T cell lymphocyte costimulation inhibitors; Ig: immunoglobulin; LTE: longterm extension; NA: not applicable; IR: incidence rate (events per 100 patient-yrs).